The classification of melanocytic lesions has long relied on three established categories: melanoma, dysplastic nevus, and common nevus. However, there is increasing evidence suggesting that a subset of tumors does not clearly fall within these definitions.
Clinical dermatologist and dermatopathologist Dr. Michael Piepkorn is among those who’ve advocated for a more precise framework for certain atypical lesions. The term melanocytoma has come to describe these diagnostically ambiguous growths, reflecting both their uncertain biological behavior and the limitations of traditional criteria.
A Diagnostic Gray Zone
In routine dermatopathology, categorizing most pigmented lesions is often straightforward. However, rare tumors occasionally present histopathologic features that do not fully align with melanoma, dysplastic nevi, or benign nevi. These lesions occupy a gray zone where morphology alone does not provide a definitive answer.
Dr. Piepkorn has noted that such cases challenge even experienced clinicians. Specifically, their structural and cellular characteristics may suggest overlapping or intermediate states rather than a clear diagnosis.
Limited Experience Leads to Uncertain Outcomes
One of the main challenges in melanocytomas is the limited clinical data. Because these tumors are infrequently encountered, the collective experience needed to predict patient outcomes is often limited. Consequently, clinicians often have to make decisions without robust longitudinal studies to guide them.
This knowledge gap can complicate risk assessment. In some cases, physicians may have to balance caution with incomplete evidence when advising patients.
Potential for Progression
Although not all melanocytomas behave aggressively, it is widely assumed that at least some possess the capacity to progress. Reports in the medical literature describe rare instances where lesions initially thought to be indeterminate later demonstrated malignant behavior. This uncertainty places melanocytomas in a clinically sensitive category: they are not definitively malignant, yet they cannot be regarded as harmless. Vigilance is therefore warranted, given the possibility of transformation over time.
Representative Subtypes and Molecular Clues
Among the better-characterized examples are BAP1-deficient melanocytoma and pigmented epithelioid melanocytoma. These entities illustrate how molecular findings can complement histologic evaluation. Specialized genetic testing, including analysis of BAP1 expression, TERT promoter mutations, and BRAF V600E mutations, can offer additional insight into tumor biology.
Although not universally definitive, such testing can refine diagnostic interpretation and help stratify potential risk. These advances can be valuable tools, particularly when facing questions unresolved by conventional microscopy.
Management Through Caution
Given the uncertain natural history of melanocytomas, caution is generally advisable when implementing management strategies. Complete surgical excision is often recommended as a precautionary measure, even when the lesion does not meet strict criteria for melanoma. This approach reflects the recognition that incomplete understanding should not translate into under-treatment.
Careful follow-up may also be advised, particularly when atypical features raise concern. This measured approach prioritizes patient safety when faced with diagnostic ambiguity.
The emergence of melanocytoma as a distinct conceptual category underscores the broader shift in dermatopathology toward more nuanced classification systems. As research continues and clinical experience expands, clearer patterns may emerge to guide both diagnosis and management. For now, Dr. Michael Piepkorn advises acknowledging uncertainty while responding with informed, disciplined care.
